Receptor News and Research

RSS

New anticancer drug SU11248 shows continued response for patients with late-stage kidney cancer

Recent studies of a new anticancer drug show continued response for patients with late-stage kidney cancer. Robert Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center (MSKCC), reported a response rate of 40 percent in patients with metastatic (advanced) renal cell (kidney) cancer who received SU11248 in second-line therapy.

15 May 2005

Targeted Genetics announces new patent for Hyperlipidemia

Targeted Genetics Corporation announced today issuance of U.S. patent #6,887,463, entitled, "Methods and Compositions for Gene Therapy for the Treatment of Defects in Lipoprotein Metabolism."

11 May 2005

Research offers new molecular approaches to therapies for the most deadly cancers

Researchers at Wake Forest University Baptist Medical Center have found promising new molecular targets and treatment approaches for some of the most malignant brain tumors.

10 May 2005

Laboratory model of immune system overcomes ethical constraints on studies of hematopoietic stem cells in humans

Scientists at St. Jude Children’s Research Hospital have joined with colleagues at several other institutions to develop a laboratory model of the human immune system. This model will allow scientists to study ways for improving the results of hematopoietic stem cell (HSC) transplantation without putting patients at risk.

10 May 2005

Clues about how alcoholic behavior is “switched” on

As part of an ongoing effort to understand the biochemical basis of alcohol abuse, scientists at the U.S. Department of Energy’s Brookhaven National Laboratory have published two studies on how modulating receptors for dopamine - a chemical “signaler” in the brain’s reward circuits - affects drinking behavior in mice and rats.

9 May 2005

Simple and efficient method for creation of novel protein functions in an existing protein scaffold

By designing a molecular bridge, scientists at the University of Illinois at Urbana-Champaign have forged a successful pathway through a complex ocean of barriers: They've changed the function of a protein using a co-evolution approach.

8 May 2005

Promising new molecular targets and treatment approaches for some of the most malignant brain tumors

The first study identified a protein that seems to control the malignant features of brain tumor cells, suggesting a new treatment target for anti-cancer drugs. Researchers found that a little-known protein called Fra-1 was effective in controlling vascular endothelial growth factor D, a factor that promotes the growth of new blood vessels in most malignant brain tumors.

8 May 2005

Chronic kidney disease linked to a single gene mutation

New research in the US has found that a mutation in a single gene causes a form of chronic kidney disease.

5 May 2005

New GP contract may not improve treatment for heart failure patients

The new contract for GPs may improve identification and diagnosis of chronic heart failure, but there is a danger that it may fall short of ensuring optimal treatment for these patients, says research published this week in Postgraduate Medical Journal.

4 May 2005

Nephrogenic Syndrome of Inappropriate Antidiuresis - a new genetic disease

Two infant boys whose bodies were overloaded with excess fluid have led UCSF pediatricians to the discovery of a new genetic disease. In the process, they have discovered a rare type of mutation where different substitutions in a single amino acid cause two different, opposite genetic disorders.

4 May 2005

Study identifies possible marker for efficacy of gefitinib in lung cancer patients

Patients with advanced non–small-cell lung cancer (NSCLC) whose tumor cells contain extra copies of the epidermal growth factor receptor (EGFR) gene may be more likely to respond to the drug gefitinib (Iressa), and this high gene copy number may be an effective predictor of gefitinib efficacy, according to a new study in the May 4 issue of the Journal of the National Cancer Institute.

3 May 2005

Critical lock and key mechanism found for the assembly of tumor blood vessels

A critical lock and key mechanism that allows the final step in the completion of new blood vessel formation has been identified by a University of California, San Diego (UCSD) School of Medicine team in research that promises to lead to a new way to halt tumor growth by cutting off the tumor blood supply.

3 May 2005

Gene variant that increases colon cancer risk

A paper published in this week's Journal of Clinical Oncology says Transforming Growth Factor Beta Receptor 1*6A (TGFBR1*6A) - a mutated gene present in nearly one in eight people and the most commonly inherited cancer susceptibility gene identified so far - might be responsible for a significant proportion of familial colorectal cancers.

2 May 2005

Myogen's Ambrisentan granted orphan drug designation by Europeans

Myogen today announced that the Commission of the European Communities, with a favorable opinion of the Committee for Orphan Medicinal Products of the European Medicines Agency (EMEA), has granted orphan drug designation to ambrisentan for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension.

2 May 2005

Blocking the COX-1 enzyme might be the answer in ovarian cancer treatment

Researchers at Vanderbilt University Medical Center in a new report say that blocking the COX-1 enzyme - not COX-2 - might lead to a way to prevent and treat the most common and fatal form of ovarian cancer.

2 May 2005

Blocking the COX-1 enzyme might prevent and treat the most common and fatal form of ovarian cancer

Blocking the COX-1 enzyme - not COX-2 - might lead to a way to prevent and treat the most common and fatal form of ovarian cancer, researchers at Vanderbilt University Medical Center reported this week.

1 May 2005

Molecular mechanism that desensitizes us to cold, discovered

Mount Sinai School of Medicine researchers have discovered how the membrane protein that allows us to sense cold works and how this protein becomes desensitized so that one no longer feels the cold.

27 Apr 2005

National clinical trial examines new option for kidney cancer patients

The trial, which opened last September, offers research subjects who qualify a new, targeted therapy in addition to standard immune therapy. The drug combination is being studied in a national Phase II clinical trial led by OHSU Cancer Institute researcher Christopher Ryan, M.D., through the Southwest Oncology Group, one of the largest clinical trial cooperative groups in the United States.

27 Apr 2005

Scientists have, for the first time, induced a state of reversible metabolic hibernation in mice

Scientists at Fred Hutchinson Cancer Research Center have, for the first time, induced a state of reversible metabolic hibernation in mice. This achievement, the first demonstration of "hibernation on demand" in a mammal, ultimately could lead to new ways to treat cancer and prevent injury and death from insufficient blood supply to organs and tissues.

23 Apr 2005

Genetic variation linked to alcohol dependence

The same gene that accounts for part of a genetic risk for developing alcoholism in a U.S. population is found in a Russian population, according to a published study by a Yale School of Medicine researcher.

22 Apr 2005

Receptor News and Research

New anticancer drug SU11248 shows continued response for patients with late-stage kidney cancer

Targeted Genetics announces new patent for Hyperlipidemia

Research offers new molecular approaches to therapies for the most deadly cancers

Laboratory model of immune system overcomes ethical constraints on studies of hematopoietic stem cells in humans

Clues about how alcoholic behavior is “switched” on

Simple and efficient method for creation of novel protein functions in an existing protein scaffold

Promising new molecular targets and treatment approaches for some of the most malignant brain tumors

Chronic kidney disease linked to a single gene mutation

New GP contract may not improve treatment for heart failure patients

Nephrogenic Syndrome of Inappropriate Antidiuresis - a new genetic disease

Study identifies possible marker for efficacy of gefitinib in lung cancer patients

Critical lock and key mechanism found for the assembly of tumor blood vessels

Gene variant that increases colon cancer risk

Myogen's Ambrisentan granted orphan drug designation by Europeans

Blocking the COX-1 enzyme might be the answer in ovarian cancer treatment

Blocking the COX-1 enzyme might prevent and treat the most common and fatal form of ovarian cancer

Molecular mechanism that desensitizes us to cold, discovered

National clinical trial examines new option for kidney cancer patients

Scientists have, for the first time, induced a state of reversible metabolic hibernation in mice

Genetic variation linked to alcohol dependence

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News